Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

28 september 2018 bijgewerkt door: Marvao Medical

Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

A U.S. multi-centre post approval registry to analyse the CRBSI rate in patients with the NexSite HD Catheter for long term vascular access for hemodialysis.

Studie Overzicht

Toestand

Voltooid

Interventie / Behandeling

Gedetailleerde beschrijving

This is a U.S. multi - centre, prospective, non-randomized post approval registry. Approximately one hundred and twenty patients will be implanted with a NexSite HD catheter at four to eight U.S. sites where hemodialysis catheters are routinely implanted. Each site may enrol a maximum of 50 patients. Enrolled patients will be followed from device placement to device removal or 180 days post device placement. Patients will be enrolled once only.

The primary endpoint is CRBSI rate related to the NexSite HD catheter. Determination of infection will be decided by the investigator and if necessary adjudicated by the CEC (Clinical Events Committee) based on blood culture results, regardless of whether the catheter is removed.

Secondary endpoints for the study are

  • Successful placement and continued use of the NexSite HD device designed for use in patients requiring long term hemodialysis.
  • Healing of catheter exit site
  • Tunnel Infections
  • Exit site infections
  • Early non-infectious complications associated with CVCs
  • Late non-infectious complications associated with Central Venous Catheters

Studietype

Ingrijpend

Inschrijving (Werkelijk)

120

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • North Carolina
      • Greenville, North Carolina, Verenigde Staten, 27834
        • Eastern Nephrology Associates
      • New Bern, North Carolina, Verenigde Staten, 28542
        • Eastern Nephology Associates
      • Raleigh, North Carolina, Verenigde Staten, 27610
        • Capital Nephrology Associates
    • South Carolina
      • Orangeburg, South Carolina, Verenigde Staten, 29118
        • South Carolina Nephrology and Hypertension Center Inc
    • Texas
      • Lubbock, Texas, Verenigde Staten, 79416
        • Lubbock Vascular Access Centre
      • San Antonio, Texas, Verenigde Staten, 78215
        • Renal Associates

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 80 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. The patient shall be 18 - 80 years old.
  2. The patient requires the placement of a long term tunnelled HD catheter for administration of hemodialysis.
  3. The patient has anticipated survival in excess of 90 days from the anticipated date of catheter placement.
  4. The patient has the ability to understand the research subject information and sign a written Informed Consent form which must be obtained prior to initiation of the study.
  5. The patient receives the catheter via the internal jugular or subclavian vein.
  6. All female patients of child bearing potential must complete a negative pregnancy test and will confirm that they are not breastfeeding.

Exclusion Criteria:

  1. The patient is participating in another IRB (Institutional Review Board) clinical trial, which modifies standard-of-care treatment and/or involves an investigational device or drug.
  2. The patient has a confirmed or suspected infection, bacteraemia or septicaemia.
  3. The patient's physiology is NOT suitable for placement of the NexSite device; this will include an examination of the anatomy at the proposed catheter exit site.
  4. The patient is known or suspected to have allergies to the materials used in the construction of the device.
  5. The patient has previously suffered from coagulation issues or has had vascular surgery at the proposed placement site.
  6. The patient has received radiation treatment at the proposed catheter placement site.
  7. The patient has severe chronic obstructive lung disease.
  8. The patient is pyretic within 72 hours (temperature ≥38o C or 100.4oF) prior to placement and/or has received antimicrobial drugs within two weeks prior to catheterisation.
  9. The patient is female of child bearing potential not using adequate contraception. (Adequate contraception is defined as abstinence, intrauterine device [IUD], birth control pills, or spermicidal gel with diaphragm or condom)
  10. The patient has another indwelling catheter.
  11. The patient has non-healing diabetic foot ulcers.
  12. The patient did not give informed consent.
  13. The patient would be unavailable for follow-up.
  14. The patient is a permanent nursing home resident.
  15. The proposed access site is not the internal jugular or subclavian vein.
  16. The patient is scheduled to undergo an elective surgical procedure (other than a procedure to create a graft or fistula) within the study timeframe.
  17. Any other condition that the Investigator believes should exclude the patient from the study.
  18. The patient does not have English or Spanish as their first language.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ander
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: NexSite HD Patients
NexSite HD patient catheter device placement
Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of participants with Catheter-Related Blood Stream Infection (CRBSI)(bacteremia/fungemia) as an adverse event.
Tijdsspanne: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with a confirmed CRBSI for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of participants with adverse events associated with device placement and use.
Tijdsspanne: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with adverse events associated with device placement and for the duration of catheter use or to 180 days post device placement.
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with unhealed catheter exit sites
Tijdsspanne: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with unhealed exit sites for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with tunnel infection as an adverse event
Tijdsspanne: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with a tunnel infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with exit site infection as an adverse event
Tijdsspanne: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with a exit site infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with Pneumothorax, haemothorax, arrhythmia, air embolism or arterial perforation as an adverse event.
Tijdsspanne: 1 day of device placement
Number of participants with non-infectious catheter complications within one day of placement.
1 day of device placement
Number of participants with Catheter dislodgement, Catheter tip dislodgement and catheter thrombosis as an adverse event.
Tijdsspanne: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with late non infectious complications for the duration of catheter use or to 180 days post device placement (whichever occurs first).
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Hoofdonderzoeker: Jeffrey G Hoggard, MD, Capital Nephrology Associates

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 april 2015

Primaire voltooiing (Werkelijk)

1 september 2017

Studie voltooiing (Werkelijk)

1 juli 2018

Studieregistratiedata

Eerst ingediend

18 mei 2015

Eerst ingediend dat voldeed aan de QC-criteria

22 mei 2015

Eerst geplaatst (Schatting)

25 mei 2015

Updates van studierecords

Laatste update geplaatst (Werkelijk)

1 oktober 2018

Laatste update ingediend die voldeed aan QC-criteria

28 september 2018

Laatst geverifieerd

1 september 2018

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • TR 0147

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op Eindstadium nierziekte

Klinische onderzoeken op NexSite HD Patients

Abonneren